Cited by 1,690Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancerChromatin Remodeling and Cancer

The DOI matches its Crossref record; 115 of the 122 references it cites were found in a registry or an index.

The RB and p53 pathways in cancer

Open access

Sherr, Charles J, McCormick, Frank·2002·Cancer Cell

Open this paper in CoChat — free account Open PDF

Abstract

The life history of cancer cells encompasses a series of genetic missteps in which normal cells are progressively transformed into tumor cells that invade surrounding tissues and become malignant. Most prominent among the regulators disrupted in cancer cells are two tumor suppressors, the retinoblastoma protein (RB) and the p53 transcription factor. Here, we discuss interconnecting signaling pathways controlled by RB and p53, attempting to explain their potentially universal involvement in the etiology of cancer. Pinpointing the various ways by which the functions of RB and p53 are subverted in individual tumors should provide a rational basis for developing more refined tumor-specific therapies.

Integrity signals

Registry

Crossref · 10.1016/s1535-6108(02)00102-2

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Self-citation
Cancer Cell Cycles
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Self-citation
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“By inducing Arf and Ink4a in primary rodent fibroblasts, oncogenic Ras expression leads to growth arrest and premature senescence (Serrano et al., 1997; Ferbeyre et al., 2002).”
Background
The regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Untitled work
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585

Show all 122 references

Sorted by citations

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441
Cell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836
Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E., Kim, T., Paik, S., Haam, S., Huh, Y., & Lee, K. (2014) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,248
Acute Lymphoblastic Leukemia
Pui, C., Relling, M. V., & Downing, J. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmra023001 · Cited by 1,182
Oxidative Stress in Aging Human Skin
Rinnerthaler, M., Bischof, J., Streubel, M., Trost, A., & Richter, K. (2015) · Biomolecules · doi:10.3390/biom5020545 · Cited by 1,053
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors
Kim, J. B., Zaehres, H., Wu, G., Gentile, L., Ko, K., Sebastiano, V., Araúzo-Bravo, M. J., Ruau, D., Han, D., Zenke, M., et al. (2008) · Nature · doi:10.1038/nature07061 · Cited by 979
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
Rosenwald, A., Wright, G. W., Wiestner, A. U., Chan, W. C., Connors, J. M., Campo, E., Gascoyne, R. D., Grogan, T. M., Müller-Hermelink, H. K., Smeland, E. B., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00028-x · Cited by 913
Cell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 934
Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress
Tao, R., Coleman, M. C., Pennington, J. D., Ozden, O., Park, S.-H., Jiang, H., Kim, H.-S., Flynn, C. R., Hill, S., Hayes McDonald, W., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.12.013 · Cited by 899
Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities
Vasaikar, S., Huang, C., Wang, X., Petyuk, V. A., Savage, S. R., Wen, B., Dou, Y., Zhang, Y., Shi, Z., Arshad, O. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.030 · Cited by 799
Multiple mutations and cancer
Loeb, L. A., Loeb, K. R., & Anderson, J. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0334858100 · Cited by 762
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
Bergsagel, P. L., Kuehl, W. M., Zhan, F., Sawyer, J. R., Barlogie, B., & Shaughnessy, J. D. (2005) · Blood · doi:10.1182/blood-2005-01-0034 · Cited by 700
Tetraploidy, aneuploidy and cancer
Ganem, N. J., Storchova, Z., & Pellman, D. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2007.02.011 · Cited by 668
Mutual exclusivity analysis identifies oncogenic network modulesPreprint
Ciriello, G., Cerami, E. G., Sander, C., & Schultz, N. D. (2011) · Genome Research · doi:10.1101/gr.125567.111 · Cited by 678
Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model
Meuwissen, R., Linn, S. C., Linnoila, R. I., Zevenhoven, J., Mooi, W. J., & Berns, A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00220-4 · Cited by 643
Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase
Wang, I.-C., Chen, Y.-J., Hughes, D., Petrovic, V., Major, M. L., Park, H. J., Tan, Y., Ackerson, T., & Costa, R. H. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.10875-10894.2005 · Cited by 627
Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence
Kortlever, R. M., Higgins, P. J., & Bernards, R. (2006) · Nature Cell Biology · doi:10.1038/ncb1448 · Cited by 637
Inactivation of the p53 pathway in retinoblastoma
Laurie, N. A., Donovan, S. L., Shih, C.-S., Zhang, J., Mills, N., Fuller, C., Teunisse, A., Lam, S., Ramos, Y., Mohan, A., et al. (2006) · Nature · doi:10.1038/nature05194 · Cited by 595
The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene
Rowland, B. D., Bernards, R., & Peeper, D. S. (2005) · Nature Cell Biology · doi:10.1038/ncb1314 · Cited by 593
Advances in biology of multiple myeloma: clinical applications
Hideshima, T., Bergsagel, P. L., Kuehl, W. M., & Anderson, K. C. (2004) · Blood · doi:10.1182/blood-2004-01-0037 · Cited by 583
Molecular mechanisms underlying RB protein function
Dick, F. A., & Rubin, S. M. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3567 · Cited by 598
Genomics and Signaling Pathways in Hepatocellular Carcinoma
Villanueva, A., Newell, P. H., Chiang, D. Y., Friedman, S. L., & Llovet, J. M. (2007) · Seminars in Liver Disease · doi:10.1055/s-2006-960171 · Cited by 551
Species- and cell type-specific requirements for cellular transformation
Rangarajan, A., Hong, S. J., Gifford, A., & Weinberg, R. A. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.07.009 · Cited by 576
Vascular Cell Senescence: Contribution to Atherosclerosis
Minamino, T., & Komuro, I. (2007) · Circulation Research · doi:10.1161/01.res.0000256837.40544.4a · Cited by 542
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 544
Cyclin E in normal and neoplastic cell cycles
Hwang, H. C., & Clurman, B. E. (2005) · Oncogene · doi:10.1038/sj.onc.1208613 · Cited by 522
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513
Mitochondrial Dysfunction in Cancer
Boland, M. L., Chourasia, A. H., & Macleod, K. F. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00292 · Cited by 521
p53 and E2f: partners in life and death
Polager, S., & Ginsberg, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2718 · Cited by 498
High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics
Carvalho, C. M., Chang, J. T., Lucas, J. E., Nevins, J. R., Wang, Q., & West, M. (2008) · Journal of the American Statistical Association · doi:10.1198/016214508000000869 · Cited by 471
Proliferation of cancer cells despite CDK2 inhibition
Tetsu, O., & McCormick, F. P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00053-9 · Cited by 472
Self-citation
Cyclin D activates the Rb tumor suppressor by mono-phosphorylation
Narasimha, A. M., Kaulich, M., Shapiro, G. S., Choi, Y. J., Siciński, P., & Dowdy, S. F. (2014) · eLife · doi:10.7554/elife.02872 · Cited by 496
Nucleolus, Ribosomes, and Cancer
Montanaro, L., Treré, D., & Derenzini, M. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070752 · Cited by 456
CDK Activity Antagonizes Whi5, an Inhibitor of G1/S Transcription in Yeast
Costanzo, M., Nishikawa, J. L., Tang, X., Millman, J. S., Schub, O., Breitkreuz, K. E., Dewar, D., Rupeš, I., Andrews, B., & Tyers, M. (2004) · Cell · doi:10.1016/j.cell.2004.05.024 · Cited by 436
Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer
Wadia, J. S., & Dowdy, S. F. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.10.005 · Cited by 430
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression
Maeda, T., Hobbs, R. M., Merghoub, T., Guernah, I., Zelent, A., Cordon‐Cardo, C., Teruya‐Feldstein, J., & Pandolfi, P. P. (2005) · Nature · doi:10.1038/nature03203 · Cited by 401
Dysregulation of growth factor signaling in human hepatocellular carcinoma
Breuhahn, K., Longerich, T., & Schirmacher, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209556 · Cited by 394
p53 in neuronal apoptosis
Culmsee, C., & Mattson, M. P. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.149 · Cited by 397
DNA Replication and Oncogene-Induced Replicative Stress
Hills, S. A., & Diffley, J. F. X. (2014) · Current Biology · doi:10.1016/j.cub.2014.04.012 · Cited by 394
Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus
Berk, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1209040 · Cited by 386
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
Gumireddy, K., Reddy, M. V. R., Cosenza, S. C., Nathan, R. B., Baker, S. J., Papathi, N., Jiang, J., Holland, J. G., & Reddy, E. P. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.009 · Cited by 374
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity
O’Shea, C. C., Johnson, L., Bagus, B., Choi, S., Nicholas, C. R., Shen, A., Boyle, L., Pandey, K., Soria, C. T., Kunich, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.11.012 · Cited by 382
Self-citation
Oncogene-Induced Cell Senescence — Halting on the Road to Cancer
Mooi, W. J., & Peeper, D. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062285 · Cited by 371
Cyclin D1: polymorphism, aberrant splicing and cancer risk
Knudsen, K. E., Diehl, J. A., Haiman, C. A., & Knudsen, E. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209371 · Cited by 372
Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressorPreprint
Kalinichenko, V. V., Major, M. L., Wang, X., Petrovic, V., Kuechle, J., Yoder, H. M., Dennewitz, M. B., Shin, B., Datta, A., Raychaudhuri, P., et al. (2004) · Genes & Development · doi:10.1101/gad.1200704 · Cited by 358
Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression
Fu, Z., Malureanu, L. A., Huang, J., Wang, W., Li, H., van Deursen, J. M., Tindall, D. J., & Chen, J. (2008) · Nature Cell Biology · doi:10.1038/ncb1767 · Cited by 357
The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a lossPreprint
Terzian, T., Suh, Y., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Pelt, C. S. V., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 363
Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a
Zhang, E., Kong, R., Yin, D., You, L., Sun, M., Han, L., Xu, T., Xia, R., Yang, J., De, W., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1902 · Cited by 355
Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling
Fu, K. (2005) · Blood · doi:10.1182/blood-2005-04-1753 · Cited by 345
Tailoring to RB: tumour suppressor status and therapeutic response
Knudsen, E. S., & Knudsen, K. E. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2401 · Cited by 354
CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment
DeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., Colameco, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2258 · Cited by 343
The Forkhead Box m1 Transcription Factor Stimulates the Proliferation of Tumor Cells during Development of Lung Cancer
Kim, I., Ackerson, T. J., Ramakrishna, S., Tretiakova, M., Wang, I., Kalin, T. V., Major, M. L., Gusarova, G. A., Yoder, H. M., Costa, R. H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3003 · Cited by 338
Telomerase: A target for cancer therapeutics
Shay, J. W., & Wright, W. E. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00159-9 · Cited by 334
RNA polymerases I and III, growth control and cancer
White, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1551 · Cited by 342
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead
Goodson, W. H., Lowe, L. J., Carpenter, D. O., Gilbertson, M., Ali, A. M., Salsamendi, A. L. D. C., Lasfar, A., Carnero, A., Azqueta, A., Amedei, A., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv039 · Cited by 336
In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
Chauhan, D., Tian, Z., Zhou, B., Kuhn, D. J., Orlowski, R. Z., Raje, N. S., Richardson, P. G. G., & Anderson, K. C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0476 · Cited by 320
Long non-coding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p-E2F3 pathway
Sun, C., Li, S., Zhang, F., Xi, Y., Wang, L., Bi, Y., & Li, D. (2016) · Oncotarget · doi:10.18632/oncotarget.10108 · Cited by 312
Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein’s C-Terminal Helix
Topacio, B. R., Zatulovskiy, E. A., Cristea, S., Xie, S., Tambo, C. S., Rubin, S. M., Sage, J., Kõivomägi, M., & Skotheim, J. M. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.03.020 · Cited by 309
Cigarette smoke induces cellular senescence
Nyunoya, T., Monick, M. M., Klingelhutz, A., Yarovinsky, T. O., Cagley, J. R., & Hunninghake, G. W. (2006) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2006-0169oc · Cited by 306
E2F – at the crossroads of life and death
Polager, S., & Ginsberg, D. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.08.003 · Cited by 313
Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription
Chipuk, J. E., Maurer, U., Green, D. R., & Schüler, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00272-1 · Cited by 302
A Translational View of the Molecular Pathogenesis of Lung Cancer
Sato, M., Shames, D. S., Gazdar, A. F., & Minna, J. D. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000263718.69320.4c · Cited by 300
Molecular mechanisms of viral oncogenesis in humans
Krump, N. A., & You, J. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0064-6 · Cited by 311
Senescence, apoptosis and therapy — cutting the lifelines of cancer
Schmitt, C. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1044 · Cited by 295
Comprehensive omic characterization of breast cancer in Mexican-Hispanic women
Romero-Cordoba, S. L., Salido-Guadarrama, I., Rebollar‐Vega, R., Bautista‐Piña, V., Domínguez-Reyes, C. A., Tenorio‐Torres, A., Villegas‐Carlos, F., Fernández-López, J. C., Uribe-Figueroa, L., Alfaro-Ruíz, L. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22478-5 · Cited by 293
Defined factors induce reprogramming of gastrointestinal cancer cells
Miyoshi, N., Ishii, H., Nagai, K.-I., Hoshino, H., Mimori, K., Tanaka, F., Nagano, H., Sekimoto, M., Doki, Y., & Mori, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912407107 · Cited by 284
Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients
de Cáceres, I. I., Battagli, C., Esteller, M., Herman, J. G., Dulaimi, E., Edelson, M. I., Bergman, C. A., Ehya, H., Eisenberg, B. L., & Cairns, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1529 · Cited by 280
The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle
Henley, S. A., & Dick, F. A. (2012) · Cell Division · doi:10.1186/1747-1028-7-10 · Cited by 296
Cell cycle regulation by long non-coding RNAs
Kitagawa, M., Kitagawa, K., Kotake, Y., Niida, H., & Ohhata, T. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1423-0 · Cited by 280
Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s)
Foster, D. A., Yellen, P., Xu, L., & Saqcena, M. (2010) · Genes & Cancer · doi:10.1177/1947601910392989 · Cited by 279
Increased Levels of the FoxM1 Transcription Factor Accelerate Development and Progression of Prostate Carcinomas in both TRAMP and LADY Transgenic Mice
Kalin, T. V., Wang, I., Ackerson, T. J., Major, M. L., Detrisac, C. J., Kalinichenko, V. V., Lyubimov, A. V., & Costa, R. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3138 · Cited by 272
Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.
Collett, K., Eide, G. E., Arnes, J. B., Stefansson, I. M., Eide, J., Braaten, A. O., Aas, T., Otte, A. P., & Akslen, L. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1533 · Cited by 272
Telomere biology in healthy aging and disease
Oeseburg, H., de Boer, R. A., van Gilst, W. H., & van der Harst, P. (2009) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-009-0728-1 · Cited by 279
Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium.
Flesken‐Nikitin, A., Choi, K., Eng, J. P., Shmidt, E. N., & Nikitin, A. Y. (2003) · PubMed · Cited by 271
Cellular senescence in vivo: a barrier to tumorigenesis
Prieur, A., & Peeper, D. S. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.01.007 · Cited by 260
Molecular Profiling Uncovers a p53-Associated Role for MicroRNA-31 in Inhibiting the Proliferation of Serous Ovarian Carcinomas and Other Cancers
Creighton, C. J., Fountain, M. D., Yu, Z., Nagaraja, A. K., Zhu, H., Khan, M., Olokpa, E., Zariff, A., Gunaratne, P. H., Matzuk, M. M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3875 · Cited by 262
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 287
The Biology of Human Lymphoid Malignancies Revealed by Gene Expression Profiling
Staudt, L. M., & Davé, S. S. (2005) · Advances in immunology · doi:10.1016/s0065-2776(05)87005-1 · Cited by 262
What the nucleolus says to a tumour pathologist
Derenzini, M., Montanaro, L., & Treré, D. (2009) · Histopathology · doi:10.1111/j.1365-2559.2008.03168.x · Cited by 271
Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
Jin, X., Ding, D., Yan, Y., Li, H., Wang, B., Ma, L., Ye, Z., Ma, T., Wu, Q., Rodrigues, D. N., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.10.034 · Cited by 265
Cell cycle transcription control: DREAM/MuvB and RB-E2F complexes.
Fischer, M., & Müller, G. A. (2017) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2017.1360836 · Cited by 255
TAp63 induces senescence and suppresses tumorigenesis in vivo
Guo, X., Keyes, W. M., Papazoglu, C., Zuber, J. A., Li, W., Lowe, S. W., Vogel, H. S., & Mills, A. A. (2009) · Nature Cell Biology · doi:10.1038/ncb1988 · Cited by 251
Toward a Molecular Classification of Melanoma
Fecher, L. A., Cummings, S. D., Keefe, M. J., & Alani, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0442 · Cited by 255
Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review
Łukasik, P., Załuski, M., & Gutowska, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062935 · Cited by 262
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
Senzer, N. N., Nemunaitis, J. J., Nemunaitis, D., Bedell, C., Edelman, G. M., Barve, M. A., Nunan, R., Pirollo, K. F., Rait, A. S., & Chang, E. H. (2013) · Molecular Therapy · doi:10.1038/mt.2013.32 · Cited by 250
miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb–E2F1 activity through a feedback loop by targeting CDK6 and CDC25APreprint
Yang, X., Feng, M., Jiang, X., Wu, Z., Li, Z., Aau, M., & Yu, Q. (2009) · Genes & Development · doi:10.1101/gad.1819009 · Cited by 256
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
Knowles, M. A. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi310 · Cited by 250
Ewing Sarcomas With p53 Mutation or p16/p14ARF Homozygous Deletion: A Highly Lethal Subset Associated With Poor Chemoresponse
Huang, H.-Y., Illei, P. B., Zhao, Z., Mazumdar, M., Huvos, A. G., Healey, J. H., Wexler, L. H., Gorlick, R. G., Meyers, P. A., & Ladanyi, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.081 · Cited by 252
Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim
Zhao, Y., Tan, J. Y., Zhuang, L., Jiang, X., Liu, E. T., & Yu, Q. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505585102 · Cited by 252
CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor–Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer
Ramesh, N., Ge, Y. C., Ennist, D. L., Zhu, M., Mina, M., Ganesh, S., Reddy, P. S., & Yu, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1059 · Cited by 243
Crystal structure of human CDK4 in complex with a D-type cyclin
Day, P. J., Cleasby, A., Tickle, I. J., O’Reilly, M., Coyle, J. E., Holding, F. P., McMenamin, R. L., Yon, J. R., Chopra, R., Christoph Lengauer, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809645106 · Cited by 241
Oncogenic roles of DNA hypomethylation through the activation of cancer-germline genes
Tongelen, A. V., Loriot, A. E., & Smet, C. D. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.029 · Cited by 247
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene
Gong, X., Du, J., Parsons, S. H., Merzoug, F. F., Webster, Y., Iversen, P. W., Chio, L.-C., Horn, R. D. V., Lin, X., Blosser, W. D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0469 · Cited by 243
New therapeutic strategies for the treatment of acute lymphoblastic leukaemia
Pui, C., & Jeha, S. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2240 · Cited by 235

Authors: Sherr, C. J., & McCormick, F.
Affiliations: St. Jude Children's Research Hospital (US)
University of California, San Francisco (US)
Corresponding author: Sherr, Charles J
ORCID: Sherr, Charles J
McCormick, Frank
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2002-08
Volume: 2
Issue: 2
Pages: 103-112
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/s1535-6108(02)00102-2
OpenAlex: W1992708996
Cited by: 1,690
References: 122
Citations by year: 2026: 31 · 2025: 40 · 2024: 36 · 2023: 60 · 2022: 56 · 2021: 62 · 2020: 62 · 2019: 67 · 2018: 75 · 2017: 67 · 2016: 60 · 2015: 71 · 2014: 88 · 2013: 81 · 2012: 90
FWCI: 7.67
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 4003 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: retinoblastoma protein, p53, tumor suppressor, malignant transformation, signaling pathways, cancer etiology, tumor-specific therapy, oncogenic transformation
MeSH terms: Cell Cycle, DNA-Binding Proteins, Humans, Neoplasms, Transcription Factors, Signal Transduction, Tumor Suppressor Protein p53, Retinoblastoma Protein, Apoptosis, Cell Cycle Proteins, Cyclin-Dependent Kinase Inhibitor p16, E2F Transcription Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The RB and p53 pathways in cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks